glp-1 obesity cardiovascular news GLP-1 Agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH

Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment

25.90

★★★★☆4.8 (126)

Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies

20.59

★★★★★4.9 (98)

GLP-1 receptor agonists such as semaglutide are changing the way type 2 diabetes and obesity are treated. But these drugs have also shown a surprising ability to improve cardiovascular health — and

25.88

★★★★★5.0 (157)

Can one drug do it all? Reviewing the expanding clinical universe of GLP-1 agonists

23.87

★★★★★4.7 (84)

GLP-1 medications are known for their weight-loss effects, but fewer people may know that they could benefit the heart too. In fact, Wegovy was approved by the FDA to reduce the risk

29.91

★★★★★4.9 (203)

GLP-1s Could Improve Heart Health - PAD Treatment Centers

23.59

★★★★★5.0 (176)

Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action

20.43

★★★★★4.8 (132)